Day 1Tuesday, 28 April 2026 - CT (China Time, GMT+08:00)

Founded in 2010, CellBion Co., Ltd. is a pioneer in the radiopharmaceutical industry, specializing in the development of cutting-edge radioligand therapies (RLT) to address unmet medical needs. Our mission is to transform patient care by delivering precision-targeted therapies that improve efficacy and safety, ultimately enhancing quality of life. Our flagship program, lutetium (177Lu)-labelled Pocuvotide satetraxetan, is a novel PSMA-targeted radioligand therapeutic agent designed to treat metastatic castration-resistant prostate cancer (mCRPC). By combining Lutetium-177 with our proprietary ligand-linker molecule, Pocuvotide satetraxetan selectively delivers beta-particle radiation to tumor cells with high PSMA receptors expression, while minimizing damage to healthy tissues. The unique design of Pocuvotide satetraxetan enhances therapeutic potency by reducing plasma protein binding, thereby increasing the free fraction available for efficient tumor targeting and improved target engagement, while its reduced systemic circulation time contributes to a favorable safety profile by minimizing off-target radiation exposure and associated toxicities. Built on a strong foundation in theranostics and a strategic focus on synergistic combinations with other therapeutic modalities, CellBion is advancing a differentiated pipeline aimed at redefining standards of care in oncology. Through innovation, collaboration, and a patient-first mindset, we are committed to shaping the future of radioligand therapy.

Polymed Biopharmaceuticals is focused on creating optimized PROTACs and Degrader Antibody Conjugates (DACs) with a superior therapeutic index than 1st generation PROTACs. Polymed leverages advanced technologies plus deep expertise in PROTAC and DAC design to create novel assets with optimized therapeutic properties delivering the next generation of life-changing medicines to patients with cancer and autoimmune disorders worldwide. Polymed is based in Hangzhou, China, and Cambridge, Massachusetts, and is a member of the Johnson and Johnson JLABS Innovation network.

Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.

Vibrant Therapeutics is a clinical-stage biotechnology company developing intelligent, logic-gated therapeutics designed to selectively activate in the desired disease microenvironment. Leveraging an integrated computational and experimental (“dry-wet”) R&D platform, the company is advancing a pipeline of innovative first-in-class/best-in-class programs, including masked T-cell engagers for solid tumors, and exploring broader applications of its technology across additional modalities and therapeutic areas. Founded by Larry Wang, Ph.D., co-founder of GenScript, Vibrant is led by a team of seasoned biotech executives formerly of Schering-Plough, Merck, and GenScript. Vibrant is headquartered in Guangzhou, China and Cambridge, Massachusetts.

ViroMissile is a biotech company founded in 2018 and headquartered in San Diego, California, with the goal of delivering a one-shot cure to many cancers with a single virus. Strategy: Bring attenuated vaccinia virus therapies, fine-tuned to survive in blood and to seek and destroy both primary and metastatic tumors with a one-shot cure. Clinical Summary: Our proof-of-concept candidate, IDOV-Safe, is in investigator-initiated trials (IIT) in China, where we have become the first company to demonstrate both intravenous delivery and tumor cell killing of an oncolytic virus at reasonable dosing levels. We have treated 55 patients with metastatic colorectal cancer and no further options for treatment. Of the evaluable patients, IDOV-Safe has achieved an 89% Disease Control Rate in combination with other therapies. Our flagship therapy, IDOV-Immune, has begun a Phase 1 trial in Australia, with our recent IND approval driving expansion into the United States at MD Anderson and other key sites. We have treated 5 patients with IDOV-Immune. Target Market: Initially, we intend to target deadly late-stage solid cancers, such as triple negative breast cancer and MSS colorectal cancer. The IDOV platform shows deadly efficacy in a broad array of 15 cancer types in 3D in vitro models. Competitive Advantage: Our clinical candidates address significant shortfalls with current oncolytic viruses, improving both survivability in blood and tumor killing efficacy. Delivered Intravenously, our viruses target both primary and metastatic tumors. Further, our viruses are designed to improve survivability within tumor cells, with data showing our viruses replicate in tumor cells and attack neighboring cancer cells within hours of treatment.

Phanes Therapeutics, Inc. is a clinical stage biotech company focused on innovative drug discovery and development in oncology. Currently, it is conducting three Phase 1/2 clinical trials, including the MORNINGSTAR study with its best-in-class monoclonal antibody (mAb) program, mavrostobart, the TWINPEAK study with spevatamig and the SKYBRIDGE study with peluntamig. Both spevatamig and peluntamig are first-in-class bispecific antibodies and have been granted orphan drug designations as well as Fast Track designations by the FDA.

VerImmune is developing Virus-inspired particles (ViPs), a novel, non-viral, self-assembling technology that imitates the structure of viruses to enable modular therapeutic delivery. This plug-and-play platform can carry diverse payloads for oncology, autoimmune, and chronic disease applications. VerImmune’s lead program, VERI-101, is a First-in-class ViP that harnesses CMV-specific T-cell memory to detect and destroy tumors, offering a tumor-type-agnostic approach with potential as monotherapy or in combination. Supported by strong preclinical efficacy, and positive FDA pre-IND feedback, VerImmune has raised ~$16M, including $4.5M non-dilutive from pharma partners and SBIRs. The company is currently seeking $10M Series A1 to successfully achieve FIH human POC.

EMICRO Biomedicine is a biotech company focused on the R & D, production, and commercialization of Class 1 innovative drugs for the treatment of autoimmune diseases and oncology. Since its inception in 2016, the company has remained steadfast in its mission to "Develop Innovative Medicines Affordable to All" and is committed to addressing unmet clinical needs through solid research and relentless innovation. EMICRO has established a balanced and diversified pipeline that strategically combines candidates targeting validated pathways with those against novel targets. This pipeline features a gradient development strategy spanning clinical and preclinical-stage indications, with concurrent coverage in both autoimmune diseases and oncology. The company employs nearly 60 professionals, over 60% of whom hold PhD or Master's degrees. We have assembled a fully integrated team spanning drug discovery, preclinical research, formulation development, clinical operations, and regulatory affairs. Our core R&D and management team members possess extensive, long-term experience and a proven track record of distinguished achievements in their respective fields. EMICRO operates a comprehensive laboratory facility exceeding 4,000 square meters, integrating multiple functional modules and equipped with over 200 state-of-the-art instruments. This infrastructure fully supports the entire workflow from initial drug discovery to pilot-scale production.

Excalipoint Therapeutics is a clinical-stage biotechnology company dedicated to the discovery and development of next-generation innovative T-cell engager (TCE) therapies to address unmet medical needs globally.

Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg).

At Twist Bioscience, we work in service of customers who are changing the world for the better. Our innovative silicon-based DNA Synthesis Platform provides precision at a scale that is otherwise unavailable to our customers which are from the fields such as medicine, agriculture, industrial chemicals and defense. Our platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis, sequencing and therapeutics discovery, providing both the quality and quantity of the tools they need to most rapidly realize the opportunity ahead. Twist Biopharma Solutions combines high-throughput DNA synthesis technology, deep expertise in antibody engineering and in vivo, in vitro and in silico discovery methods to provide end-to-end antibody discovery solutions across the preclinical continuum and tailored to our partners’ specific needs. By leveraging our unique ability to manufacture DNA at scale, we can construct proprietary antibody libraries with discovery beginning with either in vivo or in vitro diversity. Our libraries give our partners an integral and unbiased resource for antibody therapeutic discovery and optimization. This precise and rational approach to library fabrication combined with sophisticated bioinformatics and software expertise expedites antibody discovery by decreasing risk, increasing speed, and lowering the failure rate for antibody therapeutic development. Additionally, in vivo discovery approaches including single B cell screening and hybridoma discovery enable parallel paths where multiple technology methods can be leveraged to create a panel of highly diverse antibody leads. Our automated screening and panning processes enable us to identify high affinity leads that our partners can move forward into the clinic. We also offer supporting development capabilities, including IgG conversion, expression, purification, biophysical characterization, and functional characterization.

Canton Biologics, founded in 2016, specializes in biologics CDMO services. Our comprehensive portfolio includes protein sequence optimization, cell line construction and development, upstream and downstream process development, analytical method development, formulation process development, technology and QC method transfer, as well as pilot-scale and commercial manufacturing. Supported by an international top-tier quality assurance system, we provide global biopharmaceutical companies with a one-stop service that complies with international regulatory standards, covering the entire journey from cell line construction to commercialization.

Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing a portfolio of innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific. For more information, visit www.pharming.com.

MoleculeMind is a world-leading AI (artificial intelligence) protein design platform company founded by Prof. Jinbo Xu, the pioneer of AI protein folding. The company aims to revolutionize protein design and optimization by generative AI and accordingly transform the industry of drug design and synthetic biology. MoleculeMind has developed a software system MoleculeOS, the world's first AI protein modeling and design platform that includes dozens of disruptive AI algorithms, and NewOrigin, a leadingAI protein foundational model that may interact with users through natural language. The company uses MoleculeOS and NewOrigin to design proteins for novel therapeutic and catalytic enzymes.

ABRAM Therapeutics, a spinout from The Hong Kong Polytechnic University, specializes in developing innovative recombinant protein drugs, including its lead candidate ABarginase, for the treatment of obesity and metabolic diseases.

ABarginase is a potential first-in-class biologics therapeutic—an albumin-binding human arginase developed through advanced recombinant protein engineering.

Our lead candidate, ABarginase, is a long-acting enzyme that transiently lowers blood arginine levels to induce a state of metabolic reprogramming. This metabolic stress suppresses fat synthesis, mobilizes stored fat, enhances insulin sensitivity, and reduces inflammation—directly targeting the root causes of obesity, type 2 diabetes, and severe fatty liver disease.

Leveraging its unique mechanism of action, ABarginase has demonstrated superior efficacy and greater restoration of healthy body composition compared to GLP-1 (glucagon-like peptide-1) based agents in preclinical experimental results.

The company’s innovations have garnered international acclaim, such as the Best Invention Award from the International Federation of Inventors’ Associations and a Gold Medal with Jury Congratulations at the 2023 Geneva International Exhibition of Inventions.

In April 2025, ABRAM was selected to join the Roche Accelerator and the HKSTP Incu-Bio programme, highlighting its disruptive potential in the biotech field. Recently, ABarginase demonstrated promising safety and efficacy data in its first primate study cohorts, reinforcing its potential to address unmet medical needs for millions of patients.

SapiensBio is a biotech company developing first-in-class therapies for fibrotic diseases with significant unmet medical need and multi-billion-dollar market potential. Based in South Korea, the company leverages its proprietary Sapientia™ machine-learning platform to identify novel disease mechanisms and drug targets.

Tigermed (Stock code: 300347.SZ/3347.HK) is a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry. With a broad portfolio of services and a promise of quality, from preclinical development to clinical trial to commercialization, we are collaborating with over 3,600 customers and committed to moving their development journey efficiently and cost-effectively. Tigermed currently represents a worldwide network of more than 180 locations with over 10,000 employees across Asia Pacific, Europe, North America, Latin America and Africa. We are devoted to building an integrated platform that enables the boundless possibilities for the healthcare industry, embracing challenges to fulfill our commitment to serving unmet patients’ needs, and ultimately saving lives.

Yuanqi Biology Accelerate projects from laboratory research to clinical practice in as little as 12 months – an integrated biomedical consulting service with the participation of medical and scientific experts YuanQi Bio accelerates drug development through integrated consulting, proprietary artificial intelligence (AI)-assisted study design, and a global network of compliant contract research organizations (CROs) and clinical trial centers. We help our clients reduce costs, shorten cycles, and control risk at all stages.

Your Strategic Co-Development Partner for siRNA Drug Discovery.

23+ Years of RNA Expertise.

Multiple pre-PCC siRNA pipelines for collaboration.

Features：

In house one stop siRNA drug discovery platform; Dual-targeting siRNA; Extrahepatic Delivery Systerm; Ligands Conjugation.

Experience：

10+ PCC via in house R&D and collaboration: One partnered project has secured IND approvals; One partnered project was out-licensed to MNC.

Sinotherapeutics was founded in August 2012. It is a specialty pharma focus on the R&D, registration, manufacture and commercialization of complex generic products as well as innovative formulation products (505B2). The company aims to achieve commercialize its product globally, and to provide cost-effective high-quality products to international markets. The company has launched its product in multiple markets around the world, including metabolic, oncoly and CNS products. The company has its headquarter and R&D center located in the high-tech park in Pudong Zhangjiang district, Shanghai, China. The R&D center is well setup for formulation preparations, GMP analytical labs, and GMP pilot plants.The company also has a wholly owned commercial oral solid dosage form manufacture facilities, and high-potency formulation suits, both are located in Haimen City Jiangsu Provice, and have been audited and qualified multipletimes by US FDA and Chinese NMPA.

Biocom is the indisputable leader in accelerating life science in California. We accelerate our members’ success by advocating for innovation, removing barriers to doing business, and connecting people, talent and capital.

Biolexis Therapeutics is a clinical-stage biotechnology company headquartered in Lehi, Utah. Our mission is to pioneer innovative drug therapies that transform the landscape of healthcare for individuals battling chronic diseases rooted in metabolic disorders. We are dedicated to harnessing cutting-edge research and technology to develop targeted treatments that not only alleviate symptoms but also address the underlying metabolic imbalances, empowering patients to lead healthier, more vibrant lives. Our commitment to scientific excellence, ethical integrity, and patient-centric focus drives us forward as we strive to redefine possibilities in healthcare and make a meaningful difference in the lives of millions worldwide.

PegBio is a biotechnology company focused on the discovery and development of innovative therapies for chronic diseases, with a strong emphasis on metabolic disorders such as type 2 diabetes, obesity, and metabolic dysfunction-associated steatohepatitis (MASH). The company was founded in 2008 in China and is now a public company listed on the Hong Kong Stock Exchange (HKEX: 2565). PegBio develops long-acting peptide therapeutics and multi-target metabolic drugs, leveraging in-house research and development capabilities. Its pipeline includes several clinical and preclinical candidates targeting metabolic and chronic diseases. The company’s lead asset PB-119 (visepegenatide) is a long-acting GLP-1 receptor agonist being developed for type 2 diabetes and obesity, while other programs include therapies for MASH, opioid-induced constipation, and rare metabolic disorders. The company’s strategy focuses on innovative metabolic therapeutics, global partnerships, and pipeline expansion, aiming to deliver differentiated treatments for large chronic disease markets worldwide.

Shaperon is a clinical-stage biotechnology company headquartered in Seoul, South Korea, focused on the development of innovative therapies for immune and inflammatory diseases with high unmet medical need. Leveraging deep expertise in immunology and inflammatory signaling, Shaperon builds differentiated programs spanning both small molecules and next-generation biologics. Shaperon’s core pipeline is built around novel small-molecule GPCR19 positive allosteric modulators (PAMs). Unlike prior GPCR19 approaches that failed due to mixed orthosteric-allosteric binding profiles and suboptimal selectivity, Shaperon’s compounds selectively engage a distinct allosteric site, avoiding GPCR19 orthosteric related safety issues such as gallbladder filling and cardiotoxicity. This enables precise modulation of the GPCR19 receptor signaling pathway, resulting in broad suppression of inflammatory cytokine release by controlling both the priming and activation phases of inflammasome. This dual-phase regulation differentiates Shaperon's approach from other conventional inflammasome-targeting therapies that focus only on the activation phase. Shaperon has applied this strategy across multiple clinical programs advancing in inflammatory indications, including atopic dermatitis, diabetic foot ulcers, Alzheimer's disease, and idiopathic pulmonary fibrosis. In parallel, Shaperon has established a proprietary nanobody platform, NanoMab, based on alpaca-derived single-domain antibodies. Integrated with high-throughput screening and rapid optimization workflows, the NanoMab platform enables the generation of highly stable nanobodies within approximately three months. The platform supports multi-specific formats, offering modularity and flexible target engagement. NanoMabs serve as a foundation for Shaperon’s expansion into novel oncology and antiviral biologics, addressing complex diseases beyond the reach of conventional antibodies.

DeepLife is a techbio company developing artificial intelligence–powered digital twins of human cells to transform drug discovery. By integrating large-scale single-cell multi-omics data with advanced machine learning, DeepLife builds computational models that simulate how cells function, respond to disease, and react to potential therapies. The company’s platform maps complex cellular regulatory networks to identify novel drug targets, biomarkers, and therapeutic opportunities across multiple diseases. By enabling researchers to test hypotheses in silico before moving to laboratory or clinical studies, DeepLife helps pharmaceutical and biotechnology partners accelerate R&D, reduce development costs, and increase the probability of clinical success. Headquartered in Paris, DeepLife works with leading pharmaceutical companies and research institutions to apply its digital cell technology in areas such as neurology, immunology, and complex diseases. Its mission is to unlock a deeper understanding of human biology and enable the discovery of safer, more effective therapies through AI and systems biology.

Tianjin Creatron Biotechnology Co., Ltd., established in 2018, is a wholly-owned subsidiary of Beijing Creatron Pharmaceutical Research Institute. It is currently recognized as a National High-tech Enterprise and a Tianjin Eagle Enterprise. The company focuses on the research and development of its proprietary programmable nano-targeted delivery platform technology (Pg-Nano™) and its industrial application across multiple scenarios, striving to become a world-leading provider of nano-delivery solutions.

Arcera is a global company in the life sciences sector that is headquartered in Abu Dhabi, United Arab Emirates. Our vision is to bridge investment, talent, and expertise to become a leader in addressing and mitigating healthcare challenges by offering products that improve the quality and longevity of human life while fostering sustainable growth. With an operational footprint spanning over 90 countries across four continents, we bring together complementary businesses offering 2,000 branded medicines across a wide range of therapeutic areas, supported by a combined workforce of more than 6,500 people.

Opharmic Technology (HK) Limited is a Hong Kong-based platform technology company specializing in the development of ultrasound-based solutions for a variety of therapeutic areas. Founded in November 2016 as a spin-out from the Hong Kong University of Science and Technology (HKUST), the company has built 14 years of research and development experience in precise ultrasound engineering and its effects on biological systems. The company’s vision is to transform lives with innovation by developing technologies that improve patients’ well-being and empower healthcare providers alike. Core Platforms: MeticTouch® — The world’s first non-invasive ultrasound-mediated ocular drug delivery system. It provides a turnkey solution to replace invasive eye injections for retinal diseases (e.g., wet AMD, diabetic macular edema), with excellent compatibility across existing and new drug products and no reformulation required. MeticStim® — A contactless ultrasound platform for precise cell stimulation, with applications in myopia control, regenerative medicine, and oncology cell therapy.

Dr. Reddy’s Laboratories is a global pharmaceutical company focused on delivering affordable and innovative medicines across generics, specialty, biologics, and consumer health. Guided by its purpose, “Good Health Can’t Wait,” the company is transforming into a patient-centric, innovation-driven organization. Its vision is to make medicines accessible to everyone while evolving into a discovery-led global pharma leader, and its mission is to accelerate access to high-quality, affordable, and innovative treatments that address unmet patient needs and improve outcomes. With a presence in over 80+ countries, a workforce of around 27,000 employees, and a reach of more than 750 million patients annually, Dr. Reddy’s combines global scale with strong R&D and manufacturing capabilities to deliver impactful healthcare solutions worldwide.

Triovance is a late-stage preclinical biotechnology company developing first-in-class regenerative therapies for diabetic foot ulcers and related wound-healing indications. Its lead candidate, TRV-01, is a gene-engineered living skin substitute designed to address the root biology of chronic wounds and has the potential to become a differentiated therapy in a large, underserved market

Cereno Scientific is pioneering treatments to enhance and extend life. The company’s innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the fullest. Lead candidate CS1 is an HDAC inhibitor that works through epigenetic modulation and represents a novel therapeutic approach by targeting the root mechanisms of the pulmonary arterial hypertension (PAH). CS1 is a well-tolerated oral therapy with a favorable safety profile that has shown encouraging efficacy signals in a Phase IIa trial in patients with PAH, including improvements in right heart function, functional class and patient quality of life, with early signs consistent with reverse vascular remodeling. An Expanded Access Program enables patients that have completed the Phase IIa trial to gain access to CS1. CS014 is a new chemical entity and HDAC inhibitor with a multimodal mechanism of action as an epigenetic modulator having the potential to address the underlying pathophysiology of a range of cardiovascular and pulmonary diseases with high unmet needs. CS014 showed favorable safety and tolerability profile in Phase I, development focus for Phase II is pulmonary hypertension associated with interstitial lung disease (PH-ILD). Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular diseases. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in rare thrombotic diseases. The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Company’s C